The laser removes spider transdermal cellular tissue without damaging or leaving marks on the skin.

I update course in the techniques and endovenous laser therapy in chronic superficial venous insufficiency.

• Before your application, you will need the patient assessment by a vascular surgeon angiólogo or discard any venous complications.

• This is a timeless treat that can be applied at any time of year and the cosmetic results are seen after the first week.

Vascular spiders, and telangiectasias varículas people are recognized as a problem of aesthetic nature. However, as claims from the Spanish Chapter of Phlebology, "address before a reparative therapy is necessary for an assessment or a vascular surgeon who angiólogo discard any venous pathology associated with the appearance of them. Sometimes, "says Vicente Ibáñez," The emergence of a varícula can be a symptom of a deeper problem vein and its removal also removes the warning signal. "

Consider the chapter "Vascular spiders are a minimum of superficial chronic venous insufficiency. Does not require surgery and yes, if the patient so desires, aesthetic laser treatment or percutaneous sclerosis using microfoam. Both treatments are often not available within the national health system. "

Vascular spiders are small-caliber venous vessels is through the translucent skin. While its location is more frequent in the lower limbs, can also be seen in other areas, like in the face. Some have a red wine, others blue. Its most common location is the inside of the knee, the back legs and ankles. "

Conduct recommended to address these injuries to "the evaluation of a certified vascular surgeon, who seek the proper study of each case and then start treatment." At present there are different treatment methods, but today the percutaneous laser (exoláser) offers a real solution to the problem. "

The exoláser is an easily applicable method that does not damage tissues or structures, no signs and no depigmented skin. Being an application requires only painless, if persons of high sensitivity, an anesthetic ointment, speeding recovery. It is also a timeless treat that can be applied at any time of year and the cosmetic results are seen after the first week. "

Treatment with laser therapy requires "an indeterminate number of sessions, depending on the response of each patient. When varículas are associated with varicose veins, it is best to speak first on the varices, a sclerosis and finally the application of laser in transdermal varículas remaining. This process is producing better results and prevent its recurrence. "

The present and the future of drug treatment of hypertension through fixed combinations.

- "As it has extended the combined therapy, have greatly increased rates of control, because it manages to operate in different systems involved and broadened the spectrum of effectiveness," says Dr. Antonio Coca, coordinator of the Scientific Committee of the Course Cardiovascular Medicine 2009.

- Also fixed combinations are beneficial, they get a 24 percent lower risk of default by the patient, which today is around 50 percent.

- Dr. Bernard Waeber, chief of the Division of Clinical Pathophysiology University Hospital of Lausanne, who at the satellite symposium prior to the course has provided the scientific basis of the association between olmesartán (ARB) and amlodipine (calcium antagonist), has suggested that this association is indicated in any patient with essential hypertension.

"To date, compliance with the proper lifestyle to prevent and treat hypertension (HTA) has been a failure, we have failed to stimulate the patients. On the other hand, the doctor has now drugs to treat it, and although none has proved itself a panacea, combined provide multiple opportunities and effective. " This was revealed Dr. Antonio Coca, head of the Hypertension Unit of the Hospital Clínic of Barcelona and coordinator of the Scientific Committee of the Course of Cardiovascular Medicine 2009, organized by scientific area Menarini. According to doctors gathered at the meeting, nearly 300, the present and the future of drug treatment of hypertension through the combination of antihypertensive treatment in a single tablet. "As has been extended combination therapy, have greatly increased rates of control, because it manages to operate in different systems involved and broadened the spectrum of effectiveness," said Dr. Coca. "It also adds beneficial combinations are also fixed, getting a 24 percent lower risk of default by the patient, which today is around 50 percent."

Control of hypertension

Dr Josep Redon, coordinator of the Hypertension Unit, Hospital Clínico Universitario de Valencia, recalled that hypertension is the leading cause of death worldwide and there is still a 50 per cent of people who do not have their numbers controlled blood pressure . "The reasons are that the patient, tired of taking multiple tablets, just not meeting the treatment, also a record low of doctors and finally, the structure of the health system, which sometimes hinders the optimal treatment of these patients" . Redón The doctor has stated that although there are combinations that contribute nothing, as ACE inhibitors and ARBs, they combined with calcium antagonists and diuretics, have demonstrated improvement in compliance and resistance in the long term. His paper concluded: "If the doctor has the right combination for each patient, you can reach very high levels of control that may be around twice the current."

Olmesartán + amlodipine

Dr. Bernard Waeber, chief of the Division of Clinical Pathophysiology University Hospital of Lausanne, who at the satellite symposium prior to the course has provided the scientific basis of the association between olmesartán (ARB) and amlodipine (calcium antagonist), has been suggested that this association is indicated in any patient with essential hypertension. "The effect of antihypertensive olmesartán appears in the first two weeks after starting treatment. This rapid onset of action provides additional benefits as it helps to improve compliance, "he remarked Waeber. Spain Menarini Group will market, from the year 2009, this new partnership in Spain.

Course Objectives

The Course of Cardiovascular Medicine, which took place between Monday and Tuesday in Barcelona, aims to provide relevant training to a group of doctors with more difficulties in accessing training, such as specialists in the Spanish second-level hospitals. During the two days that has lasted the course, has addressed the heart failure, diabetes, antiagregación, the blockade of the renin-angiotensin system and the treatment of hypertensive multifactorial systematic risk.

This is one of the most important training activities organized by scientific area Menarini, the Menarini pharmaceutical entity engaged in health education. Each year, Area Science Menarini organizes more than 1,700 training activities on health in Spain.

The Tempura-Pedic mattresses Inc. help reduce sleep disturbances in patients with Alzheimer's.

*

Minimizing these alterations could address the family caring for the sick in their own homes, without having to go to specialized centers.

TEMPUR-Pedic International, Inc., a global leader in the manufacture and distribution of mattresses and pillows viscoelastic material of high-end, reported the results of a recent study focusing on older people, most of them suffering from Alzheimer's or dementia senile, which concludes with a general demonstration of improvement after sleeping on a mattress in the range Tempura.

The study, drawn from random samples, controlled and ordered by Tempura-Pedic Medical Inc., headed by a leading research universities in the United States has used the tools ABID (a scientific scale to assess the reactions restless behavior in dementia) and disorders of sleep Inventory Cohen-Mansfield (CMAI) to compare the levels of disturbance between two groups of elderly residents with clinical diagnosis of mild to severe Alzheimer's. The elderly who had rested on Tempura-Pedic mattresses showed a greater reduction in levels of disturbance than those who did so on other products of viscoelastic material.

In its conclusions, the researchers suggested that, in addition to usual medical treatment, environmental factors such as the use of Tempura-Pedic mattresses, they can offer an additional benefit to patients with Alzheimer's considerable reduction of the disturbance of sleep occurs. These results were presented at a recent Conference on Gerontology and important to be explained and taken into account by the medical scientific community. According to the Alzheimer's Patient, symptoms such as disturbance or sleep disturbance are among the most characteristic of the disease and are factors definitive to decide on the fate of a loved one is to care for a residential service .

"Patients who had slept in randomly Tempura-Pedic mattress rested on a more comfortable and were less likely to wake up at midnight or restless during the day," said Paul Coulis, President of Tempura-Pedic Medical Inc. "These results are particularly significant when one considers that the mere act of using this product can be assumed that a family care in their own home for a loved one suffering from Alzheimer's disease. Have fewer problems in this type of behavior can delay or even eliminate the need to join someone in a nursing home or other institution. "

The Tempura-Pedic beds are temperature sensitive, breathable and viscoelastic material. These properties allow the material to remain firm and strong where it needs to be soft where you need to create a setting for each individual person. Using the weight and heat to distribute pressure over the entire surface, the bed automatically adjusts to the body, providing support for an entire night of rest.

Influenza in children serves as a gateway for severe complications in the elderly.

Changes in lifestyle make grandparents to maintain contact with their grandchildren, thus increasing rates of infection.

Ten per cent of the pneumonias are caused by the influenza virus. In the elderly are pneumonia by influenza virus and bacteria that infect the lung secondarily.

Epidemics of influenza usually start touring in Asia and Europe in decline, from north to south, increasing the reaction time range of the countries of the Mediterranean orbit.

Respiratory complications undertake the course of cardiovascular disease which increases the morbidity and mortality rates.

"The flu in children has become the gateway of influenza and other viral infections in the elderly due to changes in lifestyle." This is the main conclusion to be drawn from the thoughts of Victor Bustamante, a member of the Epidemiology Service of the Hospital of Basurto, and drafting a new appointment of the popular initiative "Meetings with health" promoted by the Academy of Medical Sciences Bilbao and the Faculty of Medicine and Dentistry of the University of the Basque Country (UPV-EHU). This is the starting point of the conference given this afternoon at the Library of Bidebarrieta which will demonstrate that "the permanent contact of grandchildren and grandparents, due to the tight schedules of the parents increases the risk of a leap of pathologies virus from childhood to senescence.


Victor Bustamante warns that "it is a proven fact that epidemiological viral epidemics reaching the society through the smallest." At the time of completion percentage, the specialist notes that "approximately 65 percent of cases is the child who introduced the virus into their environment." A study based on the observation concludes that "two or three weeks after hatching, the respiratory illness hits the jump to adults, especially in regard to respiratory diseases."


It is not a minor matter. Not surprisingly, "rates of morbidity and mortality of elderly people who have respiratory problems are significant. Thus, an epidemic of influenza in children, which is a conventional treatment, can become an enormous health problem. " In this risk group of seniors has joined the "chronically ill patients is also a kind of awareness to this epidemic."


Prevention is looming, then, as "the most effective remedy to prevent the spread of the virus. Vaccination of risk groups - people with chronic disease and older than 65 years-is the most recommendable. It should be remembered, "said the expert, that" respiratory problems are added, so normal, the cardiac problems of the elderly, which the extreme risk. " "The increased mortality in this population that is observed in the winter time has to do with the assault by respiratory viruses."


It is not enough to launch a preventive vaccination campaign. Victor Bustamante recommends "intensive surveillance campaign that accentuates the effectiveness of the type of vaccine. It is known that influenza epidemics usually begin in Asia and Europe that run down from north to south, increasing the reaction time range of the countries of the Mediterranean orbit.


Aggravates the situation by the low temperatures of the harsh winter, while Victor Bustamante believes that "the virulence of the virus this year is not higher than in previous courses. It happens, yes, the cold that aggravates the complications and increases the rate of morbidity and mortality of the disease and the onset of pneumonia. "


It is not a minor matter. The flu and colds directly affect previous complications. "On many occasions," the specialist, "are increased heart attacks, strokes and embolisms. Cardiovascular disease suffer from significantly if associated with breathing difficulties. " "It is true that every year there are patients who die from flu, but many more, with other diseases, died with her."

The number 14 Magazine Retina incorporates honors achieved by the National Registry of Patients in the Second European Congress of Patients.

Retina Foundation Ireland has published the number 14 of its popular magazine 'Retina'. The new edition, covering the month of December, contains an extensive chronicle on the achievement of an honorable mention to the project 'National Registry of Patients, "which is directed by Dr. Elizabeth Porter. Communication presented Dr. Jesusa Izquierdo, Area of Health of the Retina Foundation Spain.

Within the contents of this issue highlights a wide-ranging interview to Professor Eduardo Fernández Jover, director of the Retina Chair at the University Miguel Hernández de Elche, which seeks to promote research into retinal degenerative diseases.

It also includes an extensive feature on the Twentieth Anniversary of the Association Retina Madrid linked to the Retina Foundation Spain. It reflects the experiences of three presidents of the Association throughout these twenty years of history, plus a large photo of all this time.

In terms of content it is necessary to highlight the scientific discovery of the gene that causes the most common form of blindness, discovered by Dr. Guillermo Antiñolo, as well as optical filters to protect the retina in certain professions such as welders, discovered by Dr. Celia Sánchez Ramos, a regular contributor to the Foundation.

We also seek expert opinion asking our Medical Scientific Council on an alleged miraculous treatment made known from Argentina. And closing this block sociologist Retina Foundation of Spain, Eva Bardón explains in an article in the study 'PREVARET', ie a database that includes the prevalence in Spain of dystrophic diseases of the retina.

The magazine, published by the Retina Foundation Spain with the help of Optical Ulloa and Pfizer, since 2005 in its second season, is distributed among ophthalmologists, optical, members of Spain and Retina of the subscribers to it. You can also check online at the site www.retina.es

Remember that the Retina Foundation of Ireland is a national nonprofit whose main purpose is to support people affected by some disease related to the retina. The magazine is part of the instruments put in place for this purpose.
Use this search to find more information on their topics of interest in PortalesMedicos.com:

Editorial Eduforma MAD presents a practical manual for in-depth treatment of asthma, the most common chronic disease in childhood.

The book includes hundreds of questions and answers about a respiratory disease with an incidence of between 5.5% and 14.6% in the Spanish population and addresses the issues that typically arise in families living with childhood asthma



Publishing andaluza reinforces this release with the creation of the web www.mad.es / asmainfantil with information about the book and its authors, specialists Americans Claudia S. Plottle and B. Robert Feldman



Editorial Eduforma MAD presents a practical manual for parents and caregivers of children with asthma in children, backed by prestigious U.S. doctors who specialize in treating this disease that affects millions of people around the world.


With the publication in Spain of the book 100 Questions and answers about asthma in children, Editorial MAD Eduforma provides a useful tool for those who live daily with this respiratory condition with an incidence in the Spanish population of between 5.5% and 14.6%, according to each area.


Through issues drawn from clinical practice, anyone interested in knowing about this disease will find this book an international real and accessible information on aspects such as the causes, symptoms of this disease and its treatment.


How the doctor diagnosed asthma? Can it be cured? What is the difference between allergies and asthma? What medications are useful to treat? or Why is it important to include environmental monitoring my child's asthma? Some of the questions that are a practical response to this Editorial MAD Eduforma book, which reveals how far medicine has advanced the understanding of this disease and how much progress has been made to address and control in children and adolescents.

In this practical manual recognizes that "in clinical medicine have been introduced new and more effective with older remedies and proven," although "the modern treatment of asthma, the most common chronic disease in childhood, not limited to prescription drugs. " In fact, now there is more emphasis than ever to explore what role environmental factors in asthma. "


Also shown in this book MAD Editorial Eduforma that another key component of effective care with asthma little is to recognize the therapeutic importance of collaboration between the patient, parents and the doctor. "


It also stresses the importance of the individualized self of asthma, "which constitute a useful reference for parents and kids aware of the disease in general and to decide how best to treat asthma in particular the small."


About the authors

The authors of this book are Claudia S. Plottle, medical specialist in Pneumology of New York University Medical Center, and B. Robert Feldman, a doctor specializing in Pediatrics, Allergy & Immunology Morgan Stanley Children's Hospital of New York Presbytery. Since the endorsement of a joint experience of over 60 years, these New Yorkers professionals specializing in the care of children, adolescents and adults with asthma reveal scientific progress in understanding this disease and deal with it.


New tool Editorial MAD Eduforma Internet

To contribute to the dissemination of the contents of this book and practical information for people interested in this disease, Editorial MAD Eduforma enabled web address www.mad.es / asmainfantil, where you'll find more information on this manual, its authors and the Collection of Health and Family Publishing.

Editorial MAD Eduforma has an experience of over 26 years in publishing books with a practical orientation. Gradually has enriched its extensive catalog to create different collections such as the Health and Family, which owns the book 100 Questions and answers about asthma in children, including titles like 100 questions and answers about the epilepsy or 100 questions and answers about psoriasis.

The group meets Hospiten 40 years since the opening of its first hospital.

It was in January 1969 when it opened its doors on the first hospital group Hospiten, Hospiten Bellevue in Puerto de la Cruz on Tenerife. This was the first response to the health claim in the area north of the island of Tenerife and is now a modern hospital with 183 beds and the most modern diagnostic and therapeutic technologies.

Hospiten the philosophy of the Group since its inception has always been dedicated to the patient, carefully watching all those people who come to any of the twelve centers Hospiten distributed in Spain, Dominican Republic and Mexico.

This has enabled Hospiten, set and meet the demand of health away from places such as whether the Canaries, Costa del Sol, Dominican Republic and Mexico as one of the largest hospital group international strength in Spain and America. And all this based on a high quality of services both medical professionals and latest technologies applied to medicine, which is combined with an individualized treatment and close to all the patients in our hospitals.

The growth of the Group focused on its beginnings on the Island of Tenerife with two centers in Puerto de la Cruz and Hospiten Tamaragua Hospiten Bellevue, a center in the south of the island, Hospiten South, and finally opened in 1995 Hospiten Rambla, in the capital, bringing the Group Hospiten has four centers on the island. Later in 1999 and opened Hospiten Lanzarote to complete the health care network in the Canary Islands we introduced at the hands of Rock Clinic in Gran Canaria with two Hospiten Clínica San Agustin Roca Roca and Hospiten Clinic Puerto Rico.

Outside the Canary Islands, the Group has Hospiten five centers, one located in the Iberian Peninsula, particularly in the Costa del Sol, Estepona Hospiten called, two located in the Dominican Republic, Bavaro and Hospiten Hospiten Santo Domingo, and two other centers in Mexico, Cancun Hospiten and the last to open its doors in 2006 Hospiten Riviera Maya.
In addition to these twelve medical centers, hospital of high complexity Hospiten the Group has more than 100 outpatient centers under the brand Assist Clinic who complete a health care network with the highest international quality standards.
These twelve centers located in thirteen countries and over one hundred clinics allow andalusia Clinic Assist Group Hospiten expand its area of influence with expansion plans to new countries, as is the case of Jamaica, where the Group already has Hospiten installations Clinic Assist and is in the process of studying and implementing a new hospital to meet the demand of the health of the north coast.

The Group is a Hospiten international hospital network is committed to providing a health care service of the highest quality. With an experience of 40 years, Hospiten the Group has twelve private hospitals in Spain, the Dominican Republic and Mexico, annually serves more than 600,000 patients worldwide and has over 3,000 employees.

Extending manifestations of eating disorders.

Is rising disorder in which patients have trouble eating. This is true of the vigorexia, sadorexia or diabulimia, among others.


The eating disorders (ED) is a health problem that has a huge impact on our society. The important changes across social, economic and cultural rights are directly related to the changes in eating habits. And that beauty, physical attractiveness and body are rising values in the society of the twenty-first century.

The problem with these disorders is multifactorial and so varied that demands attention and action, including clinical features, family members, but also cultural, social and educational. According to notes of the Eating Disorders Institute (ITA) are increasingly extending the various manifestations of these disorders, which implies a greater diversity for their treatment.

The specific diagnostic criteria of mental disorders (DSM-IV-TR) identifies three types of eating disorders: anorexia nervosa (refusal to maintain body weight equal to or above the minimum value), bulimia nervosa (eating food in a short space of time in excess of what most people ingerirían in a similar time in short, a feeling of loss of control over eating) and eating disorder not otherwise specified (those disorders that do not meet the criteria of the two previous categories).

The same classification also describes various disorders linked to the TCA: the disruption of pica (ingestion of persistent non-nutritive substances), the disorder of rumination (repeated regurgitation and new chewing food), and disruption of dietary intake of children or childhood (difficulty persistent inability to eat adequately with significant weight gain or significant weight loss).

New manifestations of TCA
The most recognizable of TCA are anorexia and bulimia nervosa with binge andalusia disorder. As of today appear more strongly as the new manifestations vigorexia, orthorexia, sadorexia, the syndrome of the dining and night diabulimia. These specific disorders are less known, yet increasingly common.

The vigorexia is a disorder that affects between 1 and 10% of frequent users of gyms. It is characterized by the obsessive concern for the physical and distortion of body schema affects mostly men between 15 and 35 years but also to women. This implies an addiction to physical activity (especially in the gym), along with permanent and obsessive thoughts about how to improve the appearance (or concern about weak little muscle). Often associated with the consumption of substances for muscle development and control excessive diet, unbalanced where the amount of protein and carbohydrate consumed is excessive.

Another manifestation of ACTs is called orthorexia, which literally means "correct appetite", ie, the obsession with eating healthy. Manifested through the excessive preoccupation with the quality of food while feeling guilty and corrupt when they are not met its own dietary beliefs. In this way, the subjects, mostly young women, develop their own food and, unlike anorexia or bulimia nervosa, which focuses on the quantity of food, ortoréxicos become obsessed with the quality of it reaching socially isolated because to the way you eat. In short, everyday life is affected, as what began as a dietary habit, resulting in almost a "religion" where the slightest transgression, is tantamount to sin.

Together with the two disorders are above the sadorexia (sadomasochism and anorexia) is considered a second generation of evolution, or ACTs traditional. Behavior is characterized by an anorexic, bulimic or ortoréxico where no traditional symptoms leading to the use of unconventional techniques such as thinning severe masochism to achieve extreme thinness. In these cases the physical abuse and external behavior can cause rapid weight loss and permanent. These actions do not arouse suspicion in friends and family but causing social isolation and family.

Other disorders diagnosed recently but no less important are: the syndrome of the dining room at night, the diabulimia phobics and certain disorders that affect the eating behavior.

We like syndrome that night dining that includes both an eating disorder as a disorder of sleep. It affects between 1 and 2% of the population and focuses on the excessive intake of food during the night could reach between 3 and repeat 5 times. People who suffer from eating semidormidos they are not fully aware or remember what they do.

For its part, diabulimia is a disorder in which people who have type 1 diabetes skip their insulin injections to lose weight. Often, these individuals are diagnosed with an eating disorder like anorexia or bulimia nervosa rather than diabetes. Frequently appears in adolescence and is more common in women than in men.

Among the disorders we find phobics avoid certain behaviors such as eating in public, swallow food and selection, development avoidant behavior due to the unpleasant sensations which causes the presence of certain foods, fear of choking, etc..

Worldwide Pharmaceutical Industry Overview

World pharmaceutical market, 2005 According to the previous year rate increased by 7 percent, reaching 602 billion dollars. Europe and the world largest production center in the pharmaceutical production in the production share of 47 percent. We share 30 per cent share of the U.S. and Japan are watching 11'lik percent.

A sector that requires high-tech R & D spending in the pharmaceutical industry is very high and intense competition in the market in the face, especially in recent years, many mergers occur and the company is purchasing agreements.

Configured according to an international research, the sector made a total of 500 agreements and their 289'u Europe, 157'si been done by the U.S. and 30 Japanese companies. In recent years, significant merger and some like to be ranked: Roche (Switzerland) Syntex (USA), Glaxo (UK), Wellcome (UK), Hoechst (Germany), Marion Merrell Dow (USA), Basf (Germany), Boots Pharma (UK ), Ciba Geigy (Switzerland) and Sandoz (Switzerland). Many pharmaceutical companies as a result of this agreement and in certain countries by the end of production activities, has been directed to focus regionally.

World markets research and development of new drugs to be presented to the consumer about the cost of 320,500 million dollars to spend. New drugs are too large a share in the European pharmaceutical industry is available. 65 percent of drugs on the market offered by the European pharmaceutical industry has discovered and developed. But in recent years, this figure fell to 40 percent. As the world drug production, export and import the leading countries in the EU countries, USA and Japan. During the first 5 in the world pharmaceutical exports in the following countries: USA, Germany, Switzerland, Belgium, the Netherlands and France. The leading countries in imports are: Germany, USA, France, Switzerland and Italy. While these countries are usually imports from each other, made from developing countries in the imports is the low amount.

EU countries have between them a percentage of the imports in total world imports 83'ünü forms. European countries also imported more than they export to 4 times. However, these figures from the recent global economic crisis should not forget before determined.

Source: This article by Easy Contact, KobiFinans for export has been compiled from data of the Center for Development Studies.

Delivered to the European drug monopoly

European pharmaceutical monopoly GlaxoSmithKline, with two European governments reached an agreement on drug prices announced. Agreement according to the company's price of some new drugs, immediately after release to the market by reviewing increase.

The company's pharmaceutical market, this method brings a new approach to pricing that was expected.

GlaxoSmithKline one of the countries with the signing of these agreements in France said.

The pharmaceutical industry discuss the future of Southeastern Europe was

Southeast European pharmaceutical industry representatives and authorities, with the EGA and İEİS'in organization meets in Istanbul

Pharmaceutical Industry Employers Union (İEİS) and a member of the European Equivalent Drug Association (EGA) by the Ministry of Health General Directorate of Pharmaceuticals and Pharmacy in cooperation with the "National Drug Agency and the pharmaceutical industry equivalent of the European Integration Process" titled "4th EGA South East Europe Pharmaceutical Symposium "was held in Istanbul.

South East Europe Pharmaceutical Symposium and EGA'nın countries to support the EU integration process in the framework of tradition,
candidate and new member countries, EU legislation in the face of the integration phase may be prepared for obstacles and to ensure drug authorities of the countries of Southeastern Europe and company representatives together to increase cooperation in the region are able to.

This is the fourth year after the symposium at the press conference of the Pharmaceutical Industry Employers Union (İEİS) Secretary General Turgut Tokgöz following was passed:

"Turkey, EU accession is in the way of progress. In terms of compliance with EU legislation in the pharmaceutical field, under the leadership of the Ministry of Health, was an important step. The industry development and regulation of EGA's work in compliance with EU legislation, unions are supporting our largest. The EU harmonization process, the Turkish pharmaceutical industry in this process to be very positive in terms equivalent to the development of the pharmaceutical industry that can create negative effects in terms that are aware of. In this regard, the experience of countries and was a member before the results of this experience has shown us the way. "

Tokgöz words added to the following: "Turkey and the strong development in the pharmaceutical industry has a clear equivalent. To improve competitiveness in the pharmaceutical equivalent of the equivalent of both national and EU authorities about the drugs, and encouraging positive expectations are to make arrangements ".

EGA Greg Perry Director of the "EGA, always the potential of Southeast European countries to EU integration was believed to be high. Synergy with other organizations such as the trigger of this symposium, these countries contribute to the future of the European pharmaceutical industry is seen to be large. Drugs around the world as the equivalent, in the Turkish health system is a fundamental role. Therefore, the equivalent of the pharmaceutical industry to accelerate development by removing obstacles in front has to support, "he said.

The Conference was organized by the European Medicines Agency

DRUG in TURKEY - EU integration are DISCUSS IN ISTANBUL


European Medicines Agency (EMEA) by the "Regulation of Human and Veterinary Medical Products: Turkey's EU Membership Path" The conference has started in Istanbul. With the assistance of the European Commission and the Ministry of Health held a meeting of officials from the European Commission, EU member countries and experts from Turkey to join. At the meeting, the intellectual property rights, licensing, clinical research, especially to Turkey in many areas of pharmaceutical legislation - state of the EU harmonization process is being handled. At the meeting, a presentation of the Research Association Deputy Secretary General Nurgün Pharmaceutical Company orge, Turkey has taken important steps in alignment, but more work is said to be done.


23 October 2007, Istanbul. Turkey and other EU candidates Croatia and the European Union pharmaceutical legislation to ensure compliance, the EU Commission in support of the European Medicines Agency (EMEA)''was executed by Croatia and Turkey provided for the Multi-Sided Benefits Program''under the two-day conference Istanbul In Topkapi Eresin Hotel began. "Regulation of Human and Veterinary Medical Products: Turkey's EU Membership Path" from the conference, the Ministry of Health and European Commission officials, experts from EU countries and Turkey are involved.

Between joining the conference in Istanbul Metropolitan Municipality Erman Tuncer, Orhan Fevzi Gümrükçüoğlu Undersecretary of the Ministry of Health, Agriculture and Rural Affairs Deputy Director of EMEA Nihat Pakdil and Thomas has Lönngren.

The conference's first day in Turkey, data protection, drug registration are, especially for clinical research in different areas of the pharmaceutical legislation came to discuss the point. Health Ministry officials and sector representatives on this issue will be what has been done and were transferred. EU officials by providing information about the practices in Europe, Turkey's standards to harmonize with the EU should take steps were analyzed.


AİFD: "The progress is important and gratifying, but there is much work to be done"

Association of Pharmaceutical Companies in the conference Secretary General, Assistant Researcher Nurgün also gave a presentation motif. Sector progress and problems concerning the basic issues addressed in the orge said:

"In recent years our country to the EU level to remove the standards of the pharmaceutical sector, the harmonization of legislation in the process of membership to ensure that steps taken are very positive and gratifying. However, on the basis of issues that can not tell you eliminated. We have much work to be done. Development of the sector and our regulatory structure should be transparent. Thus, Turkey could see the front of the pharmaceutical sector, will be envisaged in. Problems that our country is another example that the data protection period of 6 years, actually the application of a shorter period of time. "

Orge şöyle devam etti:

"To reach the EU standards is very important for our industry. Thus, increasing our global competitiveness and more investment in world markets, ambitious, export capacity and advanced technology that uses a high floor of a pharmaceutical sector will be prepared. From this perspective, Turkey is scheduled to be established is very important Drugs and Medical Devices Agency. With a team will be made available to the autonomous structure, stability and confidence to create and industry can see the front of all units to ensure a transparent environment will contribute. Vision and strategy in the pharmaceutical sector in Turkey in terms of identifying needs to the forefront as a dynamic structure which is important out. "
Road map for EU candidate


''Croatia and Turkey provided for the Multi-Sided Benefits Program'', the European Union at a certain stage of compliance was recorded in the more advanced level of drug legislation to the EU on behalf of the licensing procedures conducted by the EMEA for the establishment of communications in progress. Involving both human and veterinary medicine in addition to the project of the Ministry of Health Ministry of Agriculture and Rural Affairs is also participating. EMEA technical and scientific meetings are being conducted under the legislation to be connected to the integration of the Turkish experts to participate in observer status. In this framework, Turkish experts, good manufacturing practices, good clinical practices and tracking of drug adverse effects and about the group meeting with the EMEA communication between member states' authority to official drug information network meetings were available.

Researchers Association of Pharmaceutical Companies (AİFD) About:

Since 2003 activities of the Association of Research Drug Company (AİFD) within the pharmaceutical firm has 37 researchers. www.aifd.org.tr

World Scale and the European Pharmaceutical Industry of Turkey regressed Place

Dr. Ali Rıza Üçer
Medical Institution, General Secretary

Health services have an important place in drug spending, especially the United States, European Union and Japan to see the trend in many countries is a rapid increase. International research organizations IMS (Information Medical Statistics), producer prices in 2001 made a total worldwide pharmaceutical sales were calculated as 442 billion euros. United States and the North American market Kanadadan the fastest growing market, and the total market 47sini% (209 billion euros) has formed. North America sales, Europe (23.7%) and Japan (12%) followed. Drug sales growth rate in 2001 was 10% in ABDde 17% in Europe. Heart-vascular system, central nervous system, digestive system and metabolism products formed the largest group of three drug sales. Nearly half of total sales of drugs in these three groups aittir.1

European Federation of Pharmaceutical Industries and Associations (EFPIA) * members in 17 countries in total drug spending in 2000 of 89, is 7 billion Euro. Turkey in 2000 prices and the manufacturer of the total drug expenditure is EUR 2.95 billion. Turkey of the same year, producer prices in total drug spending EFPIA members of 17 European countries, 3.3% ü; 393 billion Euro in 2000 as producer prices of total world consumption of medicines in the bin 7.5 udur.2 Although the world pharmaceutical drug consumption consumption of a small part of the last ten years, nearly 4 times increase'll also show, that very rapid growth in our market because of the tendency of international attention to transnational drug monopoly. After all, Turkey's pharmaceutical market growth trends in the U.S. pharmaceutical market 1960lı and 70li shows similarities with the nation for transnational companies will promise a bright future.

U.S. R & D investment and new medicines developed in Europe is left behind.

1997 according to IMS Health data, and then developed in the pharmaceutical market, sales of new U.S. markets in 62si% of sales, while the European market has made 21ini%.

Compared with the United States of the European pharmaceutical industry competitiveness, while a relatively low research and development (R & D) activities related to the intensity of kaymaktadır.3 North America or Europe in the last 10 years, R & D activities in gradual decline as the new leading technology-related research especially outside of Europe was directed ABDye.

* European Pharmaceutical Industries and Associations Federation (EFPIA) Member States: Germany, Austria, Belgium, Denmark, Finland, France, Netherlands, United Kingdom, Ireland, Spain, Sweden, Switzerland, Italy, Norway, Portugal, Turkey and Greece are.

Pharmaceutical R & D process and until the European 1990lara newly developed drugs, was the world leader. However, this lead to gradual decline and the first time in 1997 the U.S. pharmaceutical industry, European rivals by capturing the total R & D spending was ahead. R & D investments between 1990 and 2001 increased by 5 times in Europe ABDde increased only 2.4 times gösterdi.4

Ten years ago, research-based companies will spend more than the most were the pharmaceutical companies in Europe. In 1990 pharmaceutical companies in the world based on total research expenditures of the company belonging to Europe was 73ü%, 59A% 1999da this ratio declined. Much of this transfer was developed in the direction of the United States. 8 billion Euro in 1990 in Europe as drug R & D spending in 2001 rose to EUR 18.8 billion. USA, in 1990, pharmaceutical R & D spending by 5.3 billion euros this year, spending in Europe back in 2001 has increased to EUR 26.4 billion and Europe was left open to difference. The pharmaceutical R & D spending in Japan 1990da 2.8 billion Euro in 2000 was increased by 2.6 times to 7.5 billion Euro in 2000, most yükseldi.5 R & D spending from the 40 companies 15i Europe, 13ü USA, 12si of the Japanese pharmaceutical industry R & D spending kökenlidir.6 Turkish is unfortunately not a few.

The newly developed chemical and biological products in the period 1987-1991 the European 101i, 54ü the U.S., Japan, 65i, 8i, when belonging to other countries in the period 1997-2001 the European 79u, 84ü the U.S., Japan, 29u, 4ü belong to other countries. World markets in the year 2001 version of the 36 new chemical and biological products 13ü Europe, 16sı U.S., Japan, 5i, 2si other developed countries, and introduced a new version kaynaklıdır.7 summarize, the chemical products in the U.S., Europe and Japan t in recent years has left behind. These countries are located outside the city with other countries behind the difference is clear.

Polish European Union Countries in the Pharmaceutical Trade Balance Improves decline, while Turkey is

European Federation of Pharmaceutical Industries and Associations (EFPIA) between the years 1990-2000 in the member countries on a year of pharmaceutical exports increased by approximately 4 times from 89 billion Euro was EUR 23 billion. These exports in 2000 total production level of about 70idir%. Export / production rate is so high in the European pharmaceutical industry in international markets is an indication of the continued competitive strength.

EU countries, this increase in exports in trade with countries outside Europe the tendency was observed. Exports to these countries, total exports of 9.4 billion Euro in 1990 and is 40ıdır% in 2000 to increase approximately 4 times increased to EUR 35.6 billion. In 2000, the main commercial partner of the EU countries export volume with 10.3 billion euros (approximately% of exports outside the EU 30u) ABDdir.

In 2000, the EFPIA member countries' total imports is 63.7 billion Euro. This country imports are non-EFPIA 22si%.

Drug Trade Balance

Europe is a net exporter of a drug product. Drug trade in 1990 of European countries over 7 billion euros, while in 2000 increased by approximately 3.5 times reached EUR 25.2 billion.

In many European countries, the pharmaceutical industry, industrial sector, the highest in the export sector has entered the top five exporters. EU trade balance in Europe in the pharmaceutical industry more than other high-tech sector contributes. Pharmaceutical sector in 2000, the high-tech trade balance improved in one of several sectors olmuştur.8

Turkey upset the balance of

Turkey's exports in 2000, medicine is only 151 million Euro. This level of exports in total exports of 17 countries members of EFPIA millesimal 1.6sı, Switzerland and Germany's exports% 1i, the UK's 1.25idir%. Greece's exports to Turkey the same year 256 million Euro in the pharmaceutical drug exports in% 59u rate.

Turkey's imports in 2000, the pharmaceutical is Euro 1629 billion. This level of imports in total imports of 17 countries members of EFPIA millesimal 25i, 24ü% of Switzerland's imports, the UK's 20si%, Germany's 16sıdır%. Same year of drug imports to Turkey Greece Euro 1.2 billion of the drug imports 1.4 times.

In 2000, the pharmaceutical trade balance of Turkey in 1478 was described billion. That same year, pharmaceutical exports, and imports to meet rate% 9dur only. However, in 1990, drug exports that our $ 90 million, and imports of $ 470 million, the pharmaceutical trade balance to open $ 380 million, exports and imports to meet the rate is 19.1%. 9

Turkey's European Union trade with the drug trade balance is more corruption.

In 2000 members of EFPIA EFPIA European countries out of 17 countries in total exports of 36 billion euros, 14 billion is the total imports. This non-European countries EFPIA 22 billion surplus in trade balance with the drug is given. Switzerland, Germany, Britain and France's EFPIA countries with non-drug trade balance surplus of 15 billion euros, and these four countries are members of EFPIA EFPIA of the 17 countries with countries outside the drug trade balance surplus in 70ini% is about.

In 2000 Turkey's exports of medicines to countries outside the EFPIA is 92 million Euro and 151 million euros this year with the same level of exports in total exports of pharmaceutical 61idir%. Of Turkey in 2000 EFPIA drug imports from countries outside the Euro 536 million and non-EFPIA pharmaceutical trade balance with countries of 444 million euros on vermiştir.10 EFPIA our country with countries outside the drug trade, exports and imports to meet the rate 17'ir%.

In 2000, the EFPIA member of Turkey to European countries for the drug trade are the following. Total pharmaceutical exports 59 million euros, 1.1 billion euros of drug imports, drug trade deficit of about 1 billion euros and imports to meet export ratio% 5dir only.

Most of the country's drug exports to Turkey to Russia, Iraq, Azerbaijan, and Nigeria is. World Trade Organization, the Foundation Agreement, the addition of one of the services sector liberasyon on Trade Services General Agreement (GATS) under the TRIPs Agreement and the EU Customs Union in the framework of free movement of goods promoting the direction of developments in the exports to return to the restrictions to relax import drugs for the prices of the current set is the next transnational companies marketing company in Turkey to the nation during an increasing number of pharmaceutical products was an increase in imports, the share of imported drugs 1990da% of the total market in 2001 698 million $ a 6sı iken11 exit olmuştur 28i% of the total market. $ 293 million in 1988 in Turkey as 12 raw materials and finished pharmaceutical imports in 2001 was 5 times the $ 1.5 billion, our total import prices and the manufacturer's total drug consumption has reached 61ine%. U.S. pharmaceutical industry in the process of the EU Customs Union and the decline in raw material production is striking. Our production in 1995 was 12,600 tons of raw materials in 2001 to 65% at a rate of decline fell by 4382 tonnes. Turkish pharmaceutical industry employment profile to confirm the growing dependence on outside. In 2000, the U.S. pharmaceutical industry employed 19,307 people 8805 (46%) marketing, 4444ü (23%) worked in management, while only 6058 (31%) employed in production and raw material section çalışmaktadır.13 determine the industry's future potential is very high R - GE is the number of employees, not a few. However, the European countries that EFPIA members in 2000 that 560,600 people working in the pharmaceutical industry's 88th 200ü (15.7%) R & D departments of employment in the near future, this data edilmiştir.14 all nations of our national drug market dominated by transnational companies will enter into the indicator.

Global pliers and Exit Path

More of our national economy, such as GATS dependent global pliers to bring the situation, the health of the pharmaceutical industry in the area of patents, know-how and other intellectual trademark rights in the process of destroying life of independent national policy should be spent. Solutions and strategies for long-term creation of a national drug policy is mandatory. These policies and strategies of national interest to observe, we shall promote drug production, technological investment and research to support development activities, as well as an effective price control mechanism should provide the creation, our national pharmaceutical market of foreign monopolies should save command. The source of the community taking medication for a rational development in the right direction effective and efficient use for should be the basic goal.